The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
出版年份 2019 全文链接
标题
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
作者
关键词
Guidelines, Immunotherapy, Head and neck cancer, Head and neck squamous cell carcinoma (HNSCC), Immune checkpoint inhibitor (ICI)
出版物
Journal for ImmunoTherapy of Cancer
Volume 7, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-07-15
DOI
10.1186/s40425-019-0662-5
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer
- (2019) Michael R. Cook et al. JAMA Oncology
- Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) John A. Thompson et al. Journal of the National Comprehensive Cancer Network
- Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
- (2019) Danny Rischin et al. JOURNAL OF CLINICAL ONCOLOGY
- EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
- (2019) Lisa F. Licitra et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma
- (2018) Roger B. Cohen et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
- (2018) Ranee Mehra et al. BRITISH JOURNAL OF CANCER
- Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
- (2018) M. Tazdait et al. EUROPEAN JOURNAL OF CANCER
- Pseudoprogression and hyperprogression after checkpoint blockade
- (2018) Qiaohong Wang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR
- (2018) L. Siu et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)
- (2018) Brigette B.Y. Ma et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
- (2018) Michael R. Migden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
- (2018) Robert L. Ferris et al. ORAL ONCOLOGY
- Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
- (2018) Carl Morrison et al. Journal for ImmunoTherapy of Cancer
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
- (2018) Jun Gong et al. Journal for ImmunoTherapy of Cancer
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Abstract LB-339: Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC)
- (2018) Tanguy Y. Seiwert et al. CANCER RESEARCH
- Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with HPV associated cancers.
- (2018) Julius Strauss et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetically engineered T-cell therapy for HPV-associated epithelial cancers: A first in human, phase I/II clinical trial.
- (2018) Stacey L. Doran et al. JOURNAL OF CLINICAL ONCOLOGY
- Delayed toxicities with anti-PD-1 and anti-PDL-1 immune checkpoint inhibitors (ICIs).
- (2018) Neil J. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I trial of T4 CAR T-cell immunotherapy in head and neck squamous cancer (HNSCC).
- (2018) Sophie Papa et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 2, multicenter study to evaluate the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-145) for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC).
- (2018) Rom S. Leidner et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant anti-OX40 (MEDI6469) prior to surgery in head and neck squamous cell carcinoma.
- (2018) Richard Bryan Bell et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC).
- (2018) Sean Matthew McBride et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study.
- (2018) Jean-Pascal H. Machiels et al. JOURNAL OF CLINICAL ONCOLOGY
- Preliminary toxicity data from the combination of pembrolizumab and definitive-dose radiotherapy for locally advanced head and neck cancer with contraindication to cisplatin therapy.
- (2018) Jared Weiss et al. JOURNAL OF CLINICAL ONCOLOGY
- RM-1929 photo-immunotherapy in patients with recurrent head and neck cancer: Results of a multicenter phase 2a open-label clinical trial.
- (2018) Ann M. Gillenwater et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1b/2a, multi-center, open-label study to evaluate the safety and efficacy of combination treatment with MEDI0457 (INO-3112) and durvalumab (MEDI4736) in patients with recurrent/metastatic human papilloma virus–associated head and neck squamous cell cancer.
- (2018) Charu Aggarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and preliminary efficacy of talimogene laherparepvec (T-VEC) in combination (combo) with pembrobrolizumab (Pembro) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): A multicenter, phase 1b study (MASTERKEY-232).
- (2018) Kevin J. Harrington et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with anaplastic thyroid cancer.
- (2018) Lori J. Wirth et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety evaluation of nivolumab (Nivo) concomitant with cetuximab-radiotherapy for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG 3504.
- (2018) Robert L. Ferris et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 “PembroRad” trial.
- (2018) Xu Shan Sun et al. JOURNAL OF CLINICAL ONCOLOGY
- Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck.
- (2018) Khalil Saleh et al. JOURNAL OF CLINICAL ONCOLOGY
- Avelumab-cetuximab-radiotherapy (RT) versus standards of care (SoC) in locally advanced squamous cell carcinoma of the head and neck (SCCHN): Safety phase of the randomized trial GORTEC 2017-01 (REACH).
- (2018) Yungan Tao et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II multi-site investigation of neoadjuvant pembrolizumab and adjuvant concurrent radiation and pembrolizumab with or without cisplatin in resected head and neck squamous cell carcinoma.
- (2018) Trisha Michel Wise-Draper et al. JOURNAL OF CLINICAL ONCOLOGY
- Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs standard of care (SOC) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in KEYNOTE-040.
- (2018) Ezra E.W. Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck.
- (2018) Matthew H. Taylor et al. JOURNAL OF CLINICAL ONCOLOGY
- Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
- (2018) Wenfeng Fang et al. LANCET ONCOLOGY
- Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer
- (2018) Erminia Massarelli et al. JAMA Oncology
- Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
- (2018) Pascale André et al. CELL
- Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
- (2018) Dan P. Zandberg et al. EUROPEAN JOURNAL OF CANCER
- JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer
- (2018) Yao Yu et al. Future Oncology
- Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology
- (2018) Therese B. Bevers et al. Journal of the National Comprehensive Cancer Network
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
- (2018) Ezra E W Cohen et al. LANCET
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- Immunotherapy for head and neck cancer: the future of treatment?
- (2017) Xiujie Xie et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
- (2017) Chiun Hsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer
- (2017) Reinhard Büttner et al. JOURNAL OF CLINICAL ONCOLOGY
- NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017
- (2017) David Adelstein et al. Journal of the National Comprehensive Cancer Network
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum‐Containing Chemotherapy
- (2017) Erin Larkins et al. ONCOLOGIST
- Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma
- (2017) Axel Lechner et al. Oncotarget
- Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
- (2017) Guillermo De Velasco et al. Cancer Immunology Research
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015
- (2017) et al. JAMA Oncology
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers
- (2017) Benjamin L. Maughan et al. Frontiers in Oncology
- Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
- (2017) Athanassios Argiris et al. Frontiers in Oncology
- Antitumor and Anti–Hepatitis C Viral Response After Administration of the Anti–Programmed Death 1 Antibody Pembrolizumab
- (2017) Sekwon Jang et al. Journal of Oncology Practice
- Cutaneous Squamous Cell Carcinoma: A Review of High-Risk and Metastatic Disease
- (2016) Kyle A. Burton et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- A comparative study of PD-L1 diagnostic assays in squamous cell carcinoma of the head and neck (SCCHN)
- (2016) M.J. Ratcliffe et al. ANNALS OF ONCOLOGY
- A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651
- (2016) A. Argiris et al. ANNALS OF ONCOLOGY
- Cancer immunotherapy: the beginning of the end of cancer?
- (2016) Sofia Farkona et al. BMC Medicine
- STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation
- (2016) Henrique Lemos et al. CANCER RESEARCH
- The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
- (2016) P. S. Hegde et al. CLINICAL CANCER RESEARCH
- Microsatellite Instability as a Biomarker for PD-1 Blockade
- (2016) J. C. Dudley et al. CLINICAL CANCER RESEARCH
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis
- (2016) O. Abdel-Rahman et al. CLINICAL ONCOLOGY
- RECIST 1.1—Update and clarification: From the RECIST committee
- (2016) Lawrence H. Schwartz et al. EUROPEAN JOURNAL OF CANCER
- A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors
- (2016) Omar Abdel-Rahman et al. Immunotherapy
- Clinical features and treatment strategy for HPV-related oropharyngeal cancer
- (2016) Kenji Okami International Journal of Clinical Oncology
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
- (2016) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
- (2016) Laura Q.M. Chow et al. JOURNAL OF CLINICAL ONCOLOGY
- Palliative and supportive care in head and neck cancer: United Kingdom National Multidisciplinary Guidelines
- (2016) H Cocks et al. JOURNAL OF LARYNGOLOGY AND OTOLOGY
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
- (2016) Tanguy Y Seiwert et al. LANCET ONCOLOGY
- Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment
- (2016) Shanthi Marur et al. MAYO CLINIC PROCEEDINGS
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global Epidemiology of Head and Neck Cancers: A Continuing Challenge
- (2016) Bhawna Gupta et al. ONCOLOGY
- Management and prevention of acute bleedings in the head and neck area with interventional radiology
- (2016) Katharina Storck et al. Head & Face Medicine
- Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
- (2016) Omar Abdel-Rahman et al. Therapeutic Advances in Respiratory Disease
- Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
- (2016) Noha Abdel-Wahab et al. PLoS One
- 11TiP * Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048
- (2015) A. Klochikhin et al. ANNALS OF ONCOLOGY
- A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors
- (2015) T. W. Chen et al. ANNALS OF ONCOLOGY
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
- (2015) Omar Abdel-Rahman et al. Expert Opinion On Drug Safety
- Immunotherapy for Head and Neck Squamous Cell Carcinoma
- (2015) David W. Schoppy et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
- (2015) Omar Abdel-Rahman et al. Immunotherapy
- Immunology and Immunotherapy of Head and Neck Cancer
- (2015) Robert L. Ferris JOURNAL OF CLINICAL ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment
- (2015) G. K. Pennock et al. ONCOLOGIST
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Immune Checkpoint Protein Inhibition for Cancer: Preclinical Justification for CTLA-4 and PD-1 Blockade and New Combinations
- (2015) Kathryn Baksh et al. SEMINARS IN ONCOLOGY
- Cytoskeletal protein Flightless I inhibits apoptosis, enhances tumor cell invasion and promotes cutaneous squamous cell carcinoma progression
- (2015) Zlatko Kopecki et al. Oncotarget
- PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
- (2015) Jason J. Luke et al. Oncotarget
- Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
- (2015) Luisa Carbognin et al. PLoS One
- PD-1/SHP-2 Inhibits Tc1/Th1 Phenotypic Responses and the Activation of T Cells in the Tumor Microenvironment
- (2014) J. Li et al. CANCER RESEARCH
- Combined P16 and human papillomavirus testing predicts head and neck cancer survival
- (2014) Christian R. Salazar et al. INTERNATIONAL JOURNAL OF CANCER
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck
- (2014) Dan P. Zandberg et al. ORAL ONCOLOGY
- Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma
- (2014) Joseph M. Curry et al. SEMINARS IN ONCOLOGY
- Inflammation-driven carcinogenesis is mediated through STING
- (2014) Jeonghyun Ahn et al. Nature Communications
- Global burden of deaths from Epstein-Barr virus attributable malignancies 1990-2010
- (2014) Gulfaraz Khan et al. Infectious Agents and Cancer
- Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?
- (2014) Mizuki Nishino et al. Journal for ImmunoTherapy of Cancer
- Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
- (2013) M. Nishino et al. CLINICAL CANCER RESEARCH
- The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
- (2013) Howard L. Kaufman et al. Nature Reviews Clinical Oncology
- The clinical impact of HPV tumor status upon head and neck squamous cell carcinomas
- (2013) Eleni Benson et al. ORAL ONCOLOGY
- Personalized Tumor Response Assessment in the Era of Molecular Medicine: Cancer-Specific and Therapy-Specific Response Criteria to Complement Pitfalls of RECIST
- (2012) Mizuki Nishino et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Human Papillomavirus Type 16 E6/E7-specific Cytotoxic T Lymphocytes for Adoptive Immunotherapy of HPV-associated Malignancies
- (2012) Carlos A. Ramos et al. JOURNAL OF IMMUNOTHERAPY
- The role of HPV in head and neck cancer and review of the HPV vaccine
- (2011) Gypsyamber D'Souza et al. PREVENTIVE MEDICINE
- The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
- (2011) N. Stransky et al. SCIENCE
- Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) V. Gregoire et al. ANNALS OF ONCOLOGY
- Non-melanoma skin cancer
- (2010) Vishal Madan et al. LANCET
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Effect of HPV-Associated p16INK4A Expression on Response to Radiotherapy and Survival in Squamous Cell Carcinoma of the Head and Neck
- (2009) Pernille Lassen et al. JOURNAL OF CLINICAL ONCOLOGY
- Head and Neck Cancer: Changing Epidemiology, Diagnosis, and Treatment
- (2009) Shanthi Marur et al. MAYO CLINIC PROCEEDINGS
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients
- (2009) Jean-Pierre Pignon et al. RADIOTHERAPY AND ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
- (2008) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial
- (2008) C. Fakhry et al. JNCI-Journal of the National Cancer Institute
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started